Tiziana Life Sciences Ltd

Equities

TLSA

BMG889121031

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 23/05/2024 BST			5-day change	1st Jan Change
0.7407 ^USD	-8.56%		+8.77%	+32.27%

05-10	Tiziana Life Sciences Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-25	Tiziana Life Sciences Ltd Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab	CI

Prof Chris McGuigan, Co-Founder and Non-Executive Director of Tiziana Life Sciences plc Passes Away

March 15, 2016 at 07:00 am

Tiziana Life Sciences plc announced the passing of Professor Chris McGuigan on Friday 11 March 2016. Prof. McGuigan was a co-founder of Tiziana Life Sciences and was appointed as a Non-executive Director in January 2015.

Latest news about Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	05-10	CI
Tiziana Life Sciences Ltd Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab	04-25	CI
Sector Update: Health Care Stocks Rise in Afternoon Trading	04-23	MT
Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program	04-23	MT
Tiziana Life Sciences, Ltd. Announces FDA Allowance for Additional Twenty Patients to Be Enroll in Intranasal Foralumab Multiple Sclerosis Expanded Access Program	04-23	CI
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in Its Expanded Access Program	04-22	CI
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with Pira Highlighted in Neurology	04-19	CI
Tiziana Life Sciences Ltd. Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology	04-18	CI
Tiziana Life Sciences Ltd. Announces Updated Clinical and Pet Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients	01-08	CI
Tiziana Life Sciences Seeks Patent for Combination Therapy for Inflammation Linked to Type 2 Diabetes, Obesity	01-05	MT
Tiziana Life Sciences Ltd Files New Patent Application for Combination Therapy of anti-CD3 with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation	01-05	CI
Tiziana Life Sciences Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	12-30	CI
Tiziana Life Sciences Ltd. Doses First Patient in Phase 2A Trial of Intranasal Foralumab in Multiple Sclerosis	12-19	CI
Transcript : Tiziana Life Sciences Ltd - Shareholder/Analyst Call	12-14
Tiziana Life Sciences Doses Four New Patients in Multiple-Sclerosis Program	11-30	MT
Tiziana Life Sciences Ltd. Announces Successfully Enrolled and Dosed Four New Patients with Non-Active Secondary Progressive Multiple Sclerosis	11-30	CI
Tiziana Life Sciences Says FDA Allows At-Home Use of Multiple Sclerosis Treatment; Shares Rise	18/10/23	MT
Tiziana Life Sciences Ltd. Announces Allowance by Fda for At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis Treatment	18/10/23	CI
Tiziana Life Sciences Ltd. Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab	16/10/23	CI
Tiziana Life Sciences Says Multiple Sclerosis Drug Reduced Key Biomarker Based on PET Scan Results	13/10/23	MT
Tiziana Announces Positive Qualitative Six-Month Pet Scan Results with Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed with Non-Active Secondary Progressive MS (Na-SPMS)	13/10/23	CI
Tiziana Life Sciences Initiates Phase 2a Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis	26/09/23	MT
Tiziana Life Sciences Ltd. Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis	26/09/23	CI
BMW expects higher China sales in 2023, finance chief says	02/09/23	RE
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer, Effective September 1, 2023	23/08/23	CI

Chart Tiziana Life Sciences Ltd

Duration

Period

More charts

Company Profile

Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohnâs and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TIZIANA LIFE SCIENCES LTD	+32.27%	74.3M
MODERNA, INC.	+64.92%	62.86B
IQVIA HOLDINGS INC.	-1.85%	41.38B
LONZA GROUP AG	+45.83%	40.38B
CELLTRION, INC.	-8.93%	27.64B
ICON PUBLIC LIMITED COMPANY	+13.05%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-21.96%	18.9B
BIO-TECHNE CORPORATION	+4.21%	12.67B
UNITED THERAPEUTICS CORPORATION	+25.74%	12.27B
MEDPACE HOLDINGS, INC.	+27.42%	12.07B

Other Biotechnology & Medical Research